Scale Biosciences Unveils Five Single Cell Profiling Products for Scalable RNA Studies
Scale Biosciences (Scale Bio™), a leader in scalable single cell analysis, has announced the launch of its QuantumScale Single Cell RNA kits. These next-generation products are designed to capture and process anywhere from 84,000 to 4 million cells, eliminating the need for specialized partitioning instrumentation. Powered by the company’s innovative Quantum Barcoding technology, this platform offers the most cost-effective single cell solution on the market, both on a per cell and per experiment basis. It simplifies the workflow, making it suitable for projects of any size, from small-scale studies to large research endeavors.
Scale Biosciences (Scale Bio™) is pushing the boundaries of single-cell RNA research with the introduction of its QuantumScale Single Cell RNA kits. These innovative products provide researchers with an affordable, flexible, and scalable solution for analyzing single cells, enabling large-scale cohort studies, drug screening programs, and the development of robust foundation models using diverse sample sets. The QuantumScale kits allow for a wide variety of experimental designs, including studies involving multiple conditions and experimental parameters.
Single-cell RNA sequencing (scRNA-seq) plays a critical role in understanding the complexities of biology and disease. However, traditional scRNA-seq methods have often been limited by high costs and experimental constraints, particularly when scaling up for large projects. The QuantumScale Single Cell RNA kits, powered by ScalePlex and Quantum Barcoding technology, are designed to address these challenges. These tools enable labs to run cell throughputs ranging from pilot projects to large-scale studies, empowering researchers to conduct more comprehensive studies than ever before.
Unprecedented Flexibility for Researchers
QuantumScale Single Cell RNA kits offer unmatched experimental flexibility. They leverage ScalePlex technology, allowing researchers to multiplex up to 9,216 samples in a single run. Despite the high sample throughput, the kits streamline the entire workflow, which can be completed in just 1.5 days. QuantumScale’s technology simplifies the process by consolidating multiple barcoding levels into a single plate. This approach reduces hands-on time by an impressive 75%, making single-cell studies more efficient and accessible.
In terms of affordability, the QuantumScale kits stand out in the market. At less than $100 per sample and under 1 cent per cell, these kits bring large-scale projects within reach of researchers with various budgets. This dramatic cost reduction opens the door for many more researchers to engage in single-cell studies and for large-scale, high-impact projects that were previously financially unfeasible.
“QuantumScale technology shifts the single-cell paradigm by eliminating the barriers that limited research possibilities,” said Giovanna Prout, President and CEO of Scale Biosciences. “For years, technology has dictated the types of experiments researchers could conduct. Now, with QuantumScale, researchers of any budget or skill level can explore single-cell omics, conduct small-scale experiments, or embark on larger studies with an easy-to-use workflow.”
Transforming Single-Cell Omics and Multiomics
One of the key advantages of the QuantumScale platform is its versatility, making it ideal for multiomics research. QuantumScale is an indispensable tool for unlocking new insights in a range of biological fields, offering high throughput while maintaining cost-efficiency. The flexibility it offers researchers is leading the next frontier of omics research, which includes not only RNA sequencing but also the ability to perform other omics analyses such as protein or metabolite profiling on the same samples.
This flexibility is further demonstrated through Scale Bio’s “100 Million Cell Challenge,” launched in 2024 in partnership with Ultima Genomics, NVIDIA, Chan Zuckerberg Initiative (CZI), and BioTuring. This global initiative is helping to push the limits of single-cell genomics by utilizing the QuantumScale kits to analyze millions of cells, and it is already showing significant promise in scaling immune system studies and expanding research capabilities.
Dr. John Tsang, an investigator at Yale University and CZ Biohub NY, expressed his enthusiasm about the impact of QuantumScale on large-scale immune system studies: “Scale Bio’s Quantum Barcoding technology allows us to dramatically scale our single-cell studies while maintaining cost efficiency. The ability to batch together samples and study millions of cells in parallel is transforming how we map immune health and responses across populations.”
QuantumScale Single Cell RNA Kits for Every Researcher
Scale Biosciences offers QuantumScale Single Cell RNA kits in four distinct configurations, as well as a modular offering, to meet the diverse needs of researchers. These kits are currently available for early access customers, and general shipping to all customers will begin shortly. Researchers can visit the QuantumScale product page for more detailed information, including a video, webinar, and frequently asked questions.
An Event to Highlight Scale Bio’s Commitment to Innovation
The launch of the QuantumScale Single Cell RNA kits coincides with the 2025 Advances in Genome Biology and Technology (AGBT) general meeting in Marco Island, Florida. During the meeting, Scale Bio CEO Giovanna Prout will present the company’s exciting developments in single-cell RNA technology and how it will continue to enhance researchers’ ability to conduct transformative experiments across a wide variety of biological fields. This session, which will be livestreamed, will provide further insights into how Scale Bio’s innovative tools will unlock new opportunities for research, such as expanding the range of accessible sample types and enabling studies across species.
About Scale Biosciences
Scale Biosciences is at the forefront of single-cell omics technology, empowering researchers with scalable and flexible solutions that redefine how single-cell research is conducted. Using proprietary massively parallelized barcoding technology, Scale Bio delivers innovative tools that streamline workflows, reduce costs, and accelerate scientific discoveries. By enabling multiomics research with ease, Scale Bio’s tools help researchers generate more data, analyze more samples, and explore new areas of omics. Scale Bio is headquartered in San Diego, California, and backed by leading investors in the life sciences tools sector, including ARCH Venture Partners, BNG01, and Tao Capital.
